Riaz Gillani
YOU?
Author Swipe
View article: Molecular Characterization Informs Prognosis in Patients With Localized Ewing Sarcoma: A Report From the Children's Oncology Group
Molecular Characterization Informs Prognosis in Patients With Localized Ewing Sarcoma: A Report From the Children's Oncology Group Open
PURPOSE Identifying discrete subgroups associated with treatment response and resistance in localized Ewing sarcoma (EWS) remains a challenge. The primary objective of the Children's Oncology Group (COG) biology study AEWS18B1-Q was to mol…
View article: Genomic correlates of clinical CAR-T cell activity
Genomic correlates of clinical CAR-T cell activity Open
Chimeric antigen receptor (CAR)-T cell therapies demonstrate potent anti-tumor efficacy in hematologic malignancies, yet clinical outcomes remain unpredictable due to the bespoke nature of the treatment, which is manufactured from each pat…
View article: Implementing a context-augmented large language model to guide precision cancer medicine
Implementing a context-augmented large language model to guide precision cancer medicine Open
The rapid expansion of molecularly informed therapies in oncology, coupled with evolving regulatory FDA approvals, poses a challenge for oncologists seeking to integrate precision cancer medicine into patient care. Large Language Models (L…
View article: Disruption of Microhomology-mediated End-joining in Ewing Sarcoma
Disruption of Microhomology-mediated End-joining in Ewing Sarcoma Open
SUMMARY Ewing sarcoma (EwS) is a group of bone and soft tissue cancers in children and young adults. Since EwS cells have pronounced sensitivity to radiation and chemotherapy-induced DNA damage, the role of the oncoprotein, EWS-FLI1, in DN…
View article: Molecular characterization informs prognosis in patients with localized Ewing sarcoma: A report from the Children’s Oncology Group
Molecular characterization informs prognosis in patients with localized Ewing sarcoma: A report from the Children’s Oncology Group Open
PURPOSE Identification of discrete sub-groups associated with treatment response and resistance in localized Ewing sarcoma (EWS) remains a challenge. The primary objective of the Children’s Oncology Group biology study AEWS18B1-Q was to pe…
View article: Somatic structural variants drive distinct modes of oncogenesis in melanoma
Somatic structural variants drive distinct modes of oncogenesis in melanoma Open
The diversity of structural variants (SVs) in melanoma and how they impact oncogenesis are incompletely known. We performed harmonized analysis of SVs across melanoma histologic and genomic subtypes, and we identified distinct global prope…
View article: Rare germline structural variants increase risk for pediatric solid tumors
Rare germline structural variants increase risk for pediatric solid tumors Open
A bstract Pediatric solid tumors are rare malignancies that represent a leading cause of death by disease among children in developed countries. The early age-of-onset of these tumors suggests that germline genetic factors are involved, ye…
View article: Integrative Analysis of Germline Rare Variants in Clear and Non–clear Cell Renal Cell Carcinoma
Integrative Analysis of Germline Rare Variants in Clear and Non–clear Cell Renal Cell Carcinoma Open
View article: Supplementary Table 5 from Integration of Genomic Sequencing Drives Therapeutic Targeting of PDGFRA in T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
Supplementary Table 5 from Integration of Genomic Sequencing Drives Therapeutic Targeting of PDGFRA in T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma Open
Hydrogen bonding of PDGFRA p.D842.
View article: Data from Integration of Genomic Sequencing Drives Therapeutic Targeting of PDGFRA in T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
Data from Integration of Genomic Sequencing Drives Therapeutic Targeting of PDGFRA in T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma Open
Purpose:Patients with relapsed or refractory T-cell acute lymphoblastic leukemia (T-ALL) or lymphoblastic lymphoma (T-LBL) have limited therapeutic options. Clinical use of genomic profiling provides an opportunity to identify targetable a…
View article: Supplementary Figure 2 from Integration of Genomic Sequencing Drives Therapeutic Targeting of PDGFRA in T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
Supplementary Figure 2 from Integration of Genomic Sequencing Drives Therapeutic Targeting of PDGFRA in T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma Open
PDGFRA mutant response to IL-3 withdrawal and ponatinib. Retreatment of mice with PDGFRA mutant PDX leads to response.
View article: Supplementary Table 6 from Integration of Genomic Sequencing Drives Therapeutic Targeting of PDGFRA in T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
Supplementary Table 6 from Integration of Genomic Sequencing Drives Therapeutic Targeting of PDGFRA in T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma Open
Results of bone marrow and PDX panel sequencing from patient 146.
View article: Data from Integration of Genomic Sequencing Drives Therapeutic Targeting of PDGFRA in T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
Data from Integration of Genomic Sequencing Drives Therapeutic Targeting of PDGFRA in T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma Open
Purpose:Patients with relapsed or refractory T-cell acute lymphoblastic leukemia (T-ALL) or lymphoblastic lymphoma (T-LBL) have limited therapeutic options. Clinical use of genomic profiling provides an opportunity to identify targetable a…
View article: Supplementary Table 4 from Integration of Genomic Sequencing Drives Therapeutic Targeting of PDGFRA in T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
Supplementary Table 4 from Integration of Genomic Sequencing Drives Therapeutic Targeting of PDGFRA in T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma Open
Treatment history for patient 146.
View article: Supplementary Table 1 from Integration of Genomic Sequencing Drives Therapeutic Targeting of PDGFRA in T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
Supplementary Table 1 from Integration of Genomic Sequencing Drives Therapeutic Targeting of PDGFRA in T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma Open
Description of the overall representativeness of study participants compared with previously reported studies.
View article: Supplementary Table 2 from Integration of Genomic Sequencing Drives Therapeutic Targeting of PDGFRA in T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
Supplementary Table 2 from Integration of Genomic Sequencing Drives Therapeutic Targeting of PDGFRA in T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma Open
Primers used for site directed mutagenesis. The table lists the forward and reverse primers used in the creation of PDGFRA p.D842, p.D845, and p.R383 mutations.
View article: Supplementary Figure 1 from Integration of Genomic Sequencing Drives Therapeutic Targeting of PDGFRA in T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
Supplementary Figure 1 from Integration of Genomic Sequencing Drives Therapeutic Targeting of PDGFRA in T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma Open
Thermodynamic cycle of PDGFRA mutations.
View article: Supplementary Figure 1 from Integration of Genomic Sequencing Drives Therapeutic Targeting of PDGFRA in T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
Supplementary Figure 1 from Integration of Genomic Sequencing Drives Therapeutic Targeting of PDGFRA in T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma Open
Thermodynamic cycle of PDGFRA mutations.
View article: Supplementary Table 3 from Integration of Genomic Sequencing Drives Therapeutic Targeting of PDGFRA in T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
Supplementary Table 3 from Integration of Genomic Sequencing Drives Therapeutic Targeting of PDGFRA in T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma Open
Clinical characteristics for patients reported in this study.
View article: Supplementary Table 4 from Integration of Genomic Sequencing Drives Therapeutic Targeting of PDGFRA in T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
Supplementary Table 4 from Integration of Genomic Sequencing Drives Therapeutic Targeting of PDGFRA in T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma Open
Treatment history for patient 146.
View article: Supplementary Table 5 from Integration of Genomic Sequencing Drives Therapeutic Targeting of PDGFRA in T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
Supplementary Table 5 from Integration of Genomic Sequencing Drives Therapeutic Targeting of PDGFRA in T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma Open
Hydrogen bonding of PDGFRA p.D842.
View article: Supplementary Table 2 from Integration of Genomic Sequencing Drives Therapeutic Targeting of PDGFRA in T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
Supplementary Table 2 from Integration of Genomic Sequencing Drives Therapeutic Targeting of PDGFRA in T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma Open
Primers used for site directed mutagenesis. The table lists the forward and reverse primers used in the creation of PDGFRA p.D842, p.D845, and p.R383 mutations.
View article: Supplementary Table 6 from Integration of Genomic Sequencing Drives Therapeutic Targeting of PDGFRA in T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
Supplementary Table 6 from Integration of Genomic Sequencing Drives Therapeutic Targeting of PDGFRA in T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma Open
Results of bone marrow and PDX panel sequencing from patient 146.
View article: Supplementary Table 3 from Integration of Genomic Sequencing Drives Therapeutic Targeting of PDGFRA in T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
Supplementary Table 3 from Integration of Genomic Sequencing Drives Therapeutic Targeting of PDGFRA in T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma Open
Clinical characteristics for patients reported in this study.
View article: Supplementary Figure 2 from Integration of Genomic Sequencing Drives Therapeutic Targeting of PDGFRA in T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
Supplementary Figure 2 from Integration of Genomic Sequencing Drives Therapeutic Targeting of PDGFRA in T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma Open
PDGFRA mutant response to IL-3 withdrawal and ponatinib. Retreatment of mice with PDGFRA mutant PDX leads to response.
View article: Supplementary Table 1 from Integration of Genomic Sequencing Drives Therapeutic Targeting of PDGFRA in T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
Supplementary Table 1 from Integration of Genomic Sequencing Drives Therapeutic Targeting of PDGFRA in T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma Open
Description of the overall representativeness of study participants compared with previously reported studies.
View article: Somatic structural variants driving distinct modes of oncogenesis in melanoma
Somatic structural variants driving distinct modes of oncogenesis in melanoma Open
The diversity of structural variants (SVs) in melanoma and how they impact oncogenesis are incompletely known. We performed harmonized analysis of SVs across melanoma histological and genomic subtypes, and we identified distinct global pro…
View article: Integration of Genomic Sequencing Drives Therapeutic Targeting of PDGFRA in T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
Integration of Genomic Sequencing Drives Therapeutic Targeting of PDGFRA in T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma Open
Purpose: Patients with relapsed or refractory T-cell acute lymphoblastic leukemia (T-ALL) or lymphoblastic lymphoma (T-LBL) have limited therapeutic options. Clinical use of genomic profiling provides an opportunity to identify targetable …
View article: Interplay of Mendelian and polygenic risk factors in Arab breast cancer patients
Interplay of Mendelian and polygenic risk factors in Arab breast cancer patients Open
View article: Targeted in silico characterization of fusion transcripts in tumor and normal tissues via FusionInspector
Targeted in silico characterization of fusion transcripts in tumor and normal tissues via FusionInspector Open